Scope and patent landscape for US Drug Patent 11,202,772 (duloxetine multiparticulate sprinkle with enteric coating and impurity-release limits)
US 11,202,772 covers a duloxetine-containing multi-particulate “sprinkle” dosage form designed to achieve specific dissolution and impurity release performance across defined media. The claims focus on (i) an enteric-coated drug core (duloxetine salt) in discrete units and (ii) quantitative limits on 1-naphthol (an impurity associated with duloxetine manufacturing) release after exposure to 0.1 N HCl. Independent claim 1 is the central scope driver. Dependent claims further narrow to tighter impurity limits, specific dissolution endpoints in 40% ethanol, specific enteric polymers, finishing “cushioning” layers, duloxetine loading, and discrete unit morphologies (pellets/beads/granules/minitablets).
Claim scope in force-driving terms
From the text provided, the patent’s coverage is bounded by a combination of structural elements and performance tests:
- Dosage form type: “multi-particulate sprinkle dosage form” composed of a plurality of discrete units.
- Unit architecture (baseline):
- Each unit has a drug core comprising duloxetine or a pharmaceutically acceptable salt.
- Each unit has an enteric coating layer surrounding the drug core.
- Performance constraints tied to impurity release:
- Claim 1: not more than 15% of 1-naphthol impurity is released after 6 hours in 0.1 N HCl dissolution media.
- Claim 2: not more than 5% of 1-naphthol released after 6 hours in 0.1 N HCl.
- Performance constraints tied to duloxetine dissolution in mixed alcohol:
- Claim 3: not more than 90% duloxetine released after 1 or 2 hours in 40% ethanol dissolution media.
- Claim 4: no more than 75% duloxetine within 75 minutes in media comprising 0.1 N HCl and 20% alcohol.
- Alternative unit architecture (inert core variant):
- Claim 5: each unit includes an inert core with a drug layer (duloxetine + enteric coating around the drug layer).
- In impurity-limited variant:
- Claim 6: claim 5 variant with ≤5% 1-naphthol after 4 hours in 0.1 N HCl.
- Polymer/ingredient recitations:
- Enteric polymer list recited in claims 7, 13, 17 (methacrylic acid copolymers; cellulose acetate phthalate; cellulose acetate succinate; polymethacrylic acid; HPMC/HPMCP phthalates; polyvinyl acetate phthalate; hydroxyethyl ethyl cellulose phthalate; cellulose acetate tetrahydrophthalate; acrylic resin; mixtures).
- Polymer amount: about 75% to about 99% by weight of the enteric coating in claims 8, 14, 18.
- Finishing/cushioning layer (post-enteric):
- Claims 9, 15, 19 recite a finishing layer containing cushioning agent selected from PEGs, polyoxyethylenes, colloidal/amorphous silicon dioxide, microcrystalline cellulose, polyvinyl acetate, waxes/fats/lipids/gums, mixtures.
- Amount: about 2% to about 20% of total dosage form in claims 10, 16, 20.
- Duloxetine load:
- Claim 11: duloxetine (or salt) in an amount about 20% by weight of the dosage form.
- Discrete unit morphology:
- Claim 12: discrete units are pellets, beads, particles, granules, or minitablets.
This is a relatively “mechanistic + testable” claim set: an accused product must plausibly meet both the materials/structure and the dissolution/impurity test outcomes within the cited media and time windows.
What patents protect duloxetine multi-particulate sprinkle enteric coating with 1-naphthol release limits?
US 11,202,772 is positioned as a formulation and performance-constraint patent rather than a new active ingredient or broad drug product genus claim. Its protection is concentrated in the intersection of:
- duloxetine (or salt),
- multi-particulate sprinkle (discrete units),
- enteric coating,
- quantitative 1-naphthol impurity release limits in 0.1 N HCl, and
- quantitative duloxetine release limits in alcohol-containing media.
Claim 1: the independent “scope center”
Claim 1 ties the following together:
- A plurality of discrete units.
- Each unit: drug core (duloxetine/salt) + enteric coating layer.
- 1-naphthol release ceiling: ≤15% after 6 hours in 0.1 N HCl.
In infringement analysis, claim 1 functions as the broadest available handle because it does not require:
- specific enteric polymer identity (though dependent claims do), nor
- inert core architecture (dependent claim 5), nor
- specific finishing/cushioning layer (dependent claims 9/10), nor
- specific duloxetine loading (dependent claim 11), nor
- specific dissolution endpoints in alcohol for duloxetine release (dependent claims 3/4).
Performance tests become claim “gates”
Because several limitations are expressed as “not more than X% released after Y time in Z media,” the patent’s enforceability against a competitor depends on what the competitor’s product actually does in those assays. That shifts litigation and licensing leverage toward:
- dissolution method equivalence,
- impurity quantification method comparability (how 1-naphthol is defined, measured, and reported),
- coating thickness/chemistry as it affects both enteric integrity and impurity diffusion/leaching.
What is the claim-by-claim “scope map” for US 11,202,772?
| Claim |
Core structural requirement |
Key quantitative performance limit(s) |
Practical meaning for design-arounds |
| 1 |
Discrete units; duloxetine/salt drug core + enteric coating |
1-naphthol ≤15% released after 6h in 0.1 N HCl |
Competitors must hit impurity barrier performance in acid conditions (longer time window). |
| 2 |
Claim 1 |
1-naphthol ≤5% after 6h in 0.1 N HCl |
Tighter impurity target narrows versions that can avoid claim 1 but still may require proving >15% to avoid claim 1. |
| 3 |
Claim 1 |
Duloxetine release ≤90% after 1 or 2h in 40% ethanol |
Alcohol exposure target for controlled release or delayed release behavior. |
| 4 |
Claim 1 |
Duloxetine release ≤75% within 75 min in 0.1 N HCl + 20% alcohol |
Test points emphasize robustness during challenging mixed media. |
| 5 |
Discrete units; inert core + drug layer; duloxetine layer + enteric coating |
Duloxetine release in 40% ethanol as in claim 3 (≤90% after 1 or 2h) |
Adds inert core architecture for variants; design around by using a drug core rather than inert core. |
| 6 |
Claim 5 |
1-naphthol ≤5% after 4h in 0.1 N HCl |
Tightens impurity window and time. |
| 7 |
Claim 1 |
Enteric polymer must be from listed set |
Restricts scope to particular polymer families unless equivalency is argued. |
| 8 |
Claim 7 |
Enteric polymer amount ~75–99 wt% of enteric coating |
Limits blending freedom; affects formulation. |
| 9 |
Claim 1 |
Finishing layer cushioning agent must be from listed set |
Adds post-enteric composition requirement for that dependent claim set. |
| 10 |
Claim 9 |
Cushioning agent ~2–20 wt% of total dosage form |
Constrains finishing layer loading. |
| 11 |
Claim 1 |
Duloxetine load ~20 wt% of dosage form |
Constrains total drug loading for that dependent claim set. |
| 12 |
Claim 1 |
Discrete units are pellets/beads/particles/granules/minitablets |
Narrows to common multiparticulate forms. |
| 13–20 |
Mirror 7–12 |
Polymer and/or finishing and loading and unit morphology variants |
Redundancy across claim groups to reinforce polymer/finishing constraints tied to core performance. |
When does US 11,202,772 lose exclusivity?
A complete exclusivity timeline requires the patent’s filing date, priority claims, and term adjustments, none of which are provided in the prompt. Under typical US practice, term for a US non-provisional patent runs from earliest effective filing date (subject to adjustments), but without the patent’s bibliographic dates, an accurate expiration calculation cannot be produced.
No exclusivity timeline is provided here because the necessary patent data is not included in the input.
How strong is the patent estate for duloxetine enteric multiparticulate sprinkle vs. prior art?
Based strictly on the claim language provided, strength hinges on how specifically the patent defines:
- the dosage form architecture (multi-particulate sprinkle units with enteric-coated duloxetine cores),
- the impurity release barrier objective for 1-naphthol in acid (0.1 N HCl),
- and the dissolution performance in alcohol-containing media.
The strongest-looking features for enforceability are the quantitative functional limitations on:
- 1-naphthol release after long acid exposure (6 hours) at defined pH/ionic strength (0.1 N HCl),
- duloxetine release under ethanol-stressed media (40% ethanol; 0.1 N HCl + 20% alcohol).
Those limitations are relatively “tight,” which can cut both ways:
- If competitors replicate the same performance targets, infringement risk rises.
- If competitors achieve different impurity release profiles (by different enteric polymers, plasticization, coating permeability, core composition, or manufacturing), they can potentially avoid the performance gates even if structure is similar.
What formulations are protected by US 11,202,772 (and what parts are “optional” via dependent claims)?
Protected formulation elements that are most likely required
- Multi-particulate sprinkle format.
- Discrete units each with an enteric-coated duloxetine/salt drug core (claim 1).
- Passing an acid media impurity-release threshold for 1-naphthol (claim 1).
Optional/conditional elements that tighten scope only for dependent claims
- Inert core with drug layer (claim 5).
- Specific enteric polymers (claims 7/13/17) and polymer loading (claims 8/14/18).
- Finishing cushioning layer composition and loading (claims 9/10/15/16/19/20).
- Duloxetine load at about 20 wt% (claim 11).
- Unit morphology list (claim 12).
How do generic entry risks map to this patent’s claim structure?
From a “Paragraph IV style” risk perspective, generic or branded challengers would focus on two infringement axes:
-
Structural substitution risk
A generic must produce a multi-particulate sprinkle with duloxetine cores and an enteric coating. If it uses a different drug product form (for example, non-sprinkle tablets, different unit morphology, or non-enteric release profiles), the claim 1 architecture may be avoided.
-
Performance-replication risk
Even with similar structure, the product must not exceed impurity and dissolution release ceilings. The decisive risk is whether the generic can show its product has:
- >15% 1-naphthol release after 6 hours in 0.1 N HCl (to avoid claim 1), or
- otherwise fails one of the numerical limitation tests.
Because the claim uses “not more than” ceilings, the generic’s best non-infringing posture typically involves demonstrating higher release (or different behavior) in the stated media/time windows, under validated comparable testing.
Which companies are challenging or would plausibly challenge this patent?
No litigation parties, Paragraph IV filings, or FDA label approval history are included in the prompt. Without those sources, naming specific companies would be unsupported.
What is the Orange Book status of US 11,202,772?
Orange Book status requires drug code, NDA/BLA association, and listing information for US 11,202,772. None of that is provided in the input. No Orange Book mapping is produced.
What patent litigation affects US 11,202,772?
No case caption, docket, or settlement terms are provided in the prompt. No litigation analysis is produced.
How does US 11,202,772 compare with other duloxetine enteric coating patents?
No other patent numbers or claim sets are provided, so a comparative landscape cannot be generated from the supplied input. A meaningful comparison requires at least one of:
- other duloxetine formulation patents’ claim language,
- prosecution histories,
- or a list of relevant Orange Book patents for the duloxetine product covered.
Key Takeaways
- US 11,202,772 is a duloxetine multiparticulate sprinkle enteric-coating patent that uses quantified functional performance limits as claim gates.
- Claim 1 is the key breadth driver: discrete duloxetine/salt cores with enteric coating, capped at ≤15% 1-naphthol release after 6 hours in 0.1 N HCl.
- Dependent claims narrow scope via:
- tighter impurity thresholds (≤5% after 6h or ≤5% after 4h),
- duloxetine dissolution limits in 40% ethanol and in 0.1 N HCl + 20% alcohol,
- specific enteric polymer selections and polymer loading,
- and a finishing cushioning layer composition and loading.
- Generic and reformulation risk centers on whether a competitor can avoid the numerical impurity and dissolution thresholds under the specified media and time windows, not just on whether it matches the general “enteric-coated duloxetine sprinkle” architecture.
FAQs
1) Can a competitor avoid infringement of claim 1 by changing the enteric polymer but keeping similar coating behavior?
If the product still meets the same structural elements (enteric-coated duloxetine sprinkle) and does not exceed the ≤15% 1-naphthol release after 6h in 0.1 N HCl threshold, claim 1 can still be implicated. Polymer changes alone are not a guaranteed design-around if performance targets are matched.
2) What matters more for infringement: the dissolution profile or the impurity release profile?
Claim 1 is driven by 1-naphthol release in 0.1 N HCl. Dissolution constraints in alcohol media appear in dependent claims (e.g., claims 3 and 4).
3) Are inert-core multiparticulate architectures covered?
Yes. Claim 5 adds an inert core with a drug layer and still includes the alcohol dissolution constraint. If a product uses inert cores but still meets the claim 5 performance limits, dependent-claim exposure increases.
4) Do the polymer list claims (7/13/17) limit scope to specific enteric polymers?
They limit those dependent claim sets to polymers enumerated in the claim text (and in certain claims, polymer loading is constrained to about 75% to 99% of the enteric coating).
5) Does the patent cover only pellets, or do beads/granules also fall in scope?
Claim 12 includes pellets, beads, particles, granules, or minitablets, so the claim set covers multiple multiparticulate morphologies.
References (APA)
- US Patent 11,202,772 (claims as provided in prompt).
